Asthma control with ICS-formoterol reliever versus maintenance ICS and SABA reliever therapy: a post hoc analysis of two randomised controlled trials

Hatter, L; Houghton, C; Bruce, P; Holliday, M; Eathorne, A; Pavord, I; Reddel, HK; Hancox, RJ; Braithwaite, I; Oldfield, K; Papi, A; Weatherall, M; Beasley, R; Corin, A; Fingleton, J; Hall, D; Mane, S; Martindale, J; Sabbagh, D; Sparks, J; Vohlidkova, A

Journal article

Asthma control with ICS-formoterol reliever versus maintenance ICS and SABA reliever therapy: a post hoc analysis of two randomised controlled trials

Abstract:: Background: In randomised controlled trials, as-needed inhaled corticosteroid (ICS)-formoterol reliever therapy reduces severe exacerbation risk compared with maintenance ICS plus short-acting beta2-agonist (SABA) reliever in adolescent and adult asthma, but results in slightly worse control of asthma symptoms, as measured by mean Asthma Control Questionnaire-5 (ACQ-5) score. Objective: To assess the levels and changes in asthma control for as-needed budesonide-formoterol versus maintenance budesonide plus SABA in post hoc analyses from the Novel START and PRACTICAL clinical trials. Methods: The number and proportion of participants at study end in each ACQ-5 category ('well-controlled', 'partly controlled' or 'inadequately controlled' symptoms), and in each responder category based on the minimal clinically important difference for ACQ-5 of 0.5 (improved, no change and worse) with as-needed budesonide-formoterol and maintenance budesonide plus SABA treatment were calculated. Results: With last observation carried forwards, 189/214 (88.3%) and 354/434 (81.6%) of patients in the budesonide-formoterol group had 'well-controlled' or 'partly controlled' symptoms at the end of the study, vs 183/214 (85.5%) and 358/431 (83.1%) in the budesonide maintenance group, for Novel START and PRACTICAL, respectively. The proportion of patients whose symptom control was either improved or unchanged from baseline was 190/214 (88.8%) and 368/434 (84.8%) for budesonide-formoterol, vs 185/214 (86.4%) and 376/431 (87.2%) for maintenance budesonide, in Novel START and PRACTICAL respectively. Conclusions: There were no clinically important differences in the proportions of patients with 'well-controlled' or 'partly controlled' asthma symptoms, or proportions who improved or maintained their level of control, with as-needed budesonide-formoterol versus maintenance budesonide plus SABA

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Share
Cite

Cite this record

APA Style

Hatter, L., Houghton, C., Bruce, P., Holliday, M., Eathorne, A., Pavord, I., Reddel, H. K., Hancox, R. J., Braithwaite, I., Oldfield, K., Papi, A., Weatherall, M., Beasley, R., Corin, A., Fingleton, J., Hall, D., Mane, S., Martindale, J., Sabbagh, D., … Vohlidkova, A. (2022). Asthma control with ICS-formoterol reliever versus maintenance ICS and SABA reliever therapy: a post hoc analysis of two randomised controlled trials. BMJ Open Respiratory Research, 9(1), e001271–e001271.

MLA Style

Hatter, L, et al. “Asthma Control with ICS-Formoterol Reliever versus Maintenance ICS and SABA Reliever Therapy: a Post Hoc Analysis of Two Randomised Controlled Trials.” BMJ Open Respiratory Research, vol. 9, no. 1, 2022, pp. e001271–e001271.

Chicago Style

Hatter, L, C Houghton, P Bruce, et al. 2022. “Asthma Control with ICS-Formoterol Reliever versus Maintenance ICS and SABA Reliever Therapy: a Post Hoc Analysis of Two Randomised Controlled Trials.” BMJ Open Respiratory Research 9 (1): e001271–e001271.
Print